Zobrazeno 1 - 10
of 121
pro vyhledávání: ''
Publikováno v:
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-11 (2021)
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology
BackgroundThe present study investigated the ameliorative effect of melittin, a major polypeptide in the venom of honeybee (Apis mellifera), on isoniazid-(INH) and rifampicin-(RIF) induced hepatotoxicity in male albino rats.MethodThirty rats (140-200
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-5 (2021)
BMC Cancer
BMC Cancer
Background Chemotherapy induced nausea- vomiting (CINV) is considered as the most common, feared and most troublesome side effect of chemotherapy. NEPA (NEtupitant 300 mg + PAlonosetron 0.50 mg) is the first commercially available oral fixed-dose com
Autor:
Helena Erlandsson Harris, Karin Palmblad, Erik Sundberg, AnnaCarin Horne, Hanna Schierbeck, Ulf Andersson, Jan-Inge Henter
Publikováno v:
Molecular Medicine, Vol 27, Iss 1, Pp 1-13 (2021)
Molecular Medicine
Molecular Medicine
Background Macrophage activation syndrome (MAS) is a potentially fatal complication of systemic inflammation. HMGB1 is a nuclear protein released extracellularly during proinflammatory lytic cell death or secreted by activated macrophages, NK cells,
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Novel meso-substituted porphyrin derivatives and its potential use in photodynamic therapy of cancer
Autor:
Gustavo Hernán Calvo, Pablo Vallecorsa, Daniel A. Sáenz, M. Belén Ballatore, Edgardo N. Durantini, Gabriela Di Venosa, Darío D. Ferreyra, Adriana Casas, Leandro Mamone
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Cancer
BMC Cancer
Background Photodynamic therapy (PDT) is an anticancer treatment that utilizes the interaction of light and a photosensitiser (PS), promoting tumour cell death mediated by generation of reactive oxygen species. In this study, we evaluated the in vitr
Autor:
James N. Nyariki, Alfred Orina Isaac, Ngalla Jillani, Victoria K. Mwaeni, George Isanda Omwenga, Mathew Piero Ngugi
Publikováno v:
BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-19 (2021)
BMC Pharmacology & Toxicology
BMC Pharmacology & Toxicology
Background Arsenic poisoning affects millions of people. The inorganic forms of arsenic are more toxic. Treatment for arsenic poisoning relies on chelation of extracellularly circulating arsenic molecules by 2,3-dimecaptosuccinic acid (DMSA). As a ph
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
BackgroundThe purpose of this retrospective study was to evaluate the survival outcomes of pembrolizumab (PEM) plus enzalutamide (ENZ) versus PEM alone in selected populations of men with previously untreated metastatic castration-resistant prostate
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-17 (2021)
BMC Cancer
BMC Cancer
Background DNA methylation is an epigenetic event involving the addition of a methyl-group to a cytosine-guanine base pair (i.e., CpG site). It is associated with different cancers. Our research focuses on studying non-small cell lung cancer hemimeth
Autor:
Adwoa Dede Asiamah, Isaac Julius Asiedu-Gyekye, Samuel Frimpong-Manso, Seth Kwabena Amponsah, Benoit Banga N'guessan, Kennedy Kwami Edem Kukuia, Joseph Adusei Sarkodie, Kwabena F.M. Opuni, Patrick Amoateng, Nana Kwame Arthur, Regina Appiah-Opong
Publikováno v:
BMC Complementary Medicine and Therapies, Vol 21, Iss 1, Pp 1-13 (2021)
BMC Complementary Medicine and Therapies
BMC Complementary Medicine and Therapies
Background Nymphaea lotus L. (N. lotus) is an aquatic plant with anecdotal reports suggesting its use in the traditional management of cancer. However, there is a paucity of data on the antioxidant, anti-inflammatory and cytotoxic properties of N. lo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background The aim of our study was to evaluate the cost-effectiveness of cabazitaxel versus abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel who had progression wi